Dosing for Colchicine in Acute Gout Attacks and Febuxostat After Flare

Colchicine Dosing for Acute Gout Attacks

The European League Against Rheumatism recommends colchicine should be started as early as possible, ideally within 12-36 hours of flare onset for maximum effectiveness 1
The recommended dosing regimen is a loading dose of 1.2 mg followed by 0.6 mg one hour later, with a total dose of 1.8 mg over a one-hour period, as suggested by the American College of Rheumatology 1
After the initial doses, continue with prophylactic dosing of 0.6 mg once or twice daily until the gout attack resolves, according to the European League Against Rheumatism 1
Low-dose colchicine (1.8 mg total over 1 hour) is as effective as higher doses with significantly fewer side effects, as reported by the American College of Rheumatology 3

Colchicine should be avoided in patients with severe renal impairment, as recommended by the European League Against Rheumatism 1
For patients with moderate renal impairment, reduce the dose to 0.6 mg with no repeat treatment for at least two weeks, according to the American College of Rheumatology 2
Colchicine should not be given to patients receiving strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin or clarithromycin, as suggested by the European League Against Rheumatism 1

Febuxostat should be initiated at a low dose and then titrated upwards until the serum uric acid (SUA) target is reached, as recommended by the European League Against Rheumatism 1
The target SUA level should be maintained at <6 mg/dL, according to the American College of Rheumatology 1
A lower SUA target (<5 mg/dL) is recommended for patients with severe gout, as suggested by the European League Against Rheumatism 1

Recommended prophylactic treatment is colchicine, 0.6 mg once or twice daily, as recommended by the European League Against Rheumatism 1
Prophylaxis should be continued for at least 6 months during ULT, according to the American College of Rheumatology 1

Failing to start colchicine within 36 hours of symptom onset significantly reduces its effectiveness, as reported by the American College of Rheumatology 2
Not adjusting colchicine dose in patients with renal impairment or those on interacting medications can lead to toxicity, as suggested by the European League Against Rheumatism 1
Failing to maintain long-term ULT after resolution of acute symptoms leads to recurrent flares, according to the European League Against Rheumatism 1